Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Market Closed 02-14 16:00:00 EST

4.25

-0.15

-3.41%

盘后4.40

+0.15+3.45%

19:54 EST

High4.56	Low4.21	Vol720.98K
Open4.46	D1 Closing4.40	Amplitude7.95%
Mkt Cap136.83M	Tradable Cap75.13M	Total Shares32.20M
T/O3.11M	T/O Rate4.08%	Tradable Shares17.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":4.25,"timestamp":1739566800000,"preClose":4.4,"halted":0,"volume":720982,"hourTrading":{"tag":"盘后","latestPrice":4.3965,"preClose":4.25,"latestTime":"19:54 EST","volume":2792,"amount":12117.0995,"timestamp":1739580859931},"delay":0,"floatShares":17677131,"shares":32195345,"eps":-1.287523,"marketStatus":"Market Closed","change":-0.15,"latestTime":"02-14 16:00:00 EST","open":4.46,"high":4.56,"low":4.21,"amount":3112889.7490526,"amplitude":0.079545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.287523,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":4.4,"preHourTrading":{"tag":"盘前","latestPrice":4.56,"preClose":4.4,"latestTime":"08:32 EST","volume":274,"amount":1235.3192182,"timestamp":1739539969318},"postHourTrading":{"tag":"盘后","latestPrice":4.3965,"preClose":4.25,"latestTime":"19:54 EST","volume":2792,"amount":12117.0995,"timestamp":1739580859931},"volumeRatio":0.8994441270558924,"impliedVol":2.1803,"impliedVolPercentile":0.7624},"requestUrl":"/m/hq/s/SGMT","defaultTab":"news","newsList":[{"id":"2508266181","title":"Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2508266181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508266181?lang=en_us&edition=fundamental","pubTime":"2025-02-04 01:27","pubTimestamp":1738603648,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A (SGMT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst De...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/uncategorized/buy-recommendation-for-sagimet-biosciences-denifanstats-unique-profile-and-undervaluation-offer-compelling-investment-opportunity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/uncategorized/buy-recommendation-for-sagimet-biosciences-denifanstats-unique-profile-and-undervaluation-offer-compelling-investment-opportunity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2506309070","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sagimet Biosciences, Sage Therapeutics, Qorvo","url":"https://stock-news.laohu8.com/highlight/detail?id=2506309070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506309070?lang=en_us&edition=fundamental","pubTime":"2025-01-27 23:49","pubTimestamp":1737992980,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sagimet Biosciences, Sage Therapeutics, QorvoEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL3N3ON13C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEE","AZPN","2NVD.UK","CNP","EVRG","NVD","NVIW.SI","3NVD.UK","ASAN","NVDU","TLN","NEE","COF","NVD3.UK","ALLK","NVD2.UK","RL","SGMT","QXO","SBAC","IRM","X","NVDA","AKRO","BECN","EQT","NVDS","VST","T","NVDY","EQIX","QRVO","NVDD","TVGN","HUT","CEG","DLR","LNG","ET"],"gpt_icon":1},{"id":"2506153377","title":"BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2506153377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506153377?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:55","pubTimestamp":1737986158,"startTime":"0","endTime":"0","summary":"BUZZ-JonesTrading starts coverage on drug developer Sagimet with 'buy' rating** JonesTrading starts coverage on drug developer Sagimet Biosciences SGMT.O with \"buy\" rating, sets PT at $42** PT represents 900% upside to stock's last close** Brokerage says co's experimental drug, denifanstat, is \"overlooked potential\" in treating metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** JonesTrading notes denifanstat has \" best-in-disease potential for fibrosis improvement as GLP-1 combo\" with \"well-derisked lead asset\" in expanding market** Brokerage says it estimates peak sales of $1.6 bln for denifanstat in 2034** SGMT fell 15.6% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nL3N3ON0XG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2506376163","title":"Sagimet Biosciences Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2506376163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506376163?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:13","pubTimestamp":1737980021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON0SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2506375740","title":"Sagimet Biosciences initiated with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2506375740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506375740?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:55","pubTimestamp":1737978942,"startTime":"0","endTime":"0","summary":"JonesResearch initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $42 price target The firm says its bullish outlook is driven b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-a-buy-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2504828514","title":"With 43% stake, Sagimet Biosciences Inc. (NASDAQ:SGMT) seems to have captured institutional investors' interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2504828514","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504828514?lang=en_us&edition=fundamental","pubTime":"2025-01-20 18:09","pubTimestamp":1737367778,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Sagimet Biosciences implies that they have significant influence...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmt/sagimet-biosciences/news/with-43-stake-sagimet-biosciences-inc-nasdaqsgmt-seems-to-ha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2095319765.USD","BK4139","LU2210150020.SGD","MNQmain","NQmain","BK4588","LU2210149790.SGD","TSYW.SI","QLD","NDAQ","NVIW.SI","IE00B3QW5Z07.USD",".IXIC","BK4585","USAW.SI","SGMT","IE00BKPKM429.USD","TQQQ","QID","IE00B64PRP62.GBP","IE00BGHQF748.EUR","USJW.SI","BK4112","PSQ","SQQQ"],"gpt_icon":1},{"id":"2503324894","title":"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503324894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503324894?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:51","pubTimestamp":1736754695,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Sagimet B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2491050154.USD","SG9999014906.USD","LU0708995401.HKD","LU0122379950.USD","LU1623119135.USD","BK4516","SG9999018857.SGD","LU0114720955.EUR","LU1712237335.SGD","SGMT","LU0823416689.USD","GB00BDT5M118.USD","LU0238689110.USD","BK4139","LU2265009873.SGD","LU0820561818.USD","LU1988902786.USD","LU2106854487.HKD","SG9999015945.SGD","LU0097036916.USD","SGXZ81514606.USD","SG9999015952.SGD","IE00B1BXHZ80.USD","LU0882574139.USD","LU0354030511.USD","LU0096364046.USD","HCSG","SGXZ99366536.SGD","BK4007","BK4599","LU1868837136.USD","LU2324357040.USD","LLY","IE0002141913.USD","SGXZ31699556.SGD","SGXZ51526630.SGD","LU1551013342.USD","SG9999014914.USD","LU1868836757.USD","LU1868836914.USD","LU1551013425.SGD","LU1917777945.USD","IE00BFTCPJ56.SGD","LU0094547139.USD","LU0417517546.SGD","LU1280957306.USD","LU2237443978.SGD","LU2468319806.SGD","LU1366192091.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2503130153","title":"Promising Potential of Denifanstat Drives Buy Rating for Sagimet Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2503130153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503130153?lang=en_us&edition=fundamental","pubTime":"2025-01-13 08:05","pubTimestamp":1736726756,"startTime":"0","endTime":"0","summary":"Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report). The ass...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-potential-of-denifanstat-drives-buy-rating-for-sagimet-biosciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-potential-of-denifanstat-drives-buy-rating-for-sagimet-biosciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2501397682","title":"BRIEF-Sagimet Biosciences Announces Oral Presentation At The 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501397682","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501397682?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:13","pubTimestamp":1736169197,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet Biosciences Announces Oral Presentation At The 9th Annual MASH-TAG 2025 ConferenceJan 6  - Sagimet Biosciences Inc SGMT.O:SAGIMET BIOSCIENCES ANNOUNCES ORAL PRESENTATION AT THE 9TH ANNUAL MASH-TAG 2025 CONFERENCESource text: nGNXbV84LfFurther company coverage: SGMT.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA2PYTPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2501239340","title":"Sagimet Biosciences Announces Oral Presentation at the 9TH Annual Mash-Tag 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239340?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA2PYTPM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2501392032","title":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501392032","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501392032?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Jan.  06, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctiona","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/06/3004574/0/en/Sagimet-Biosciences-Announces-Oral-Presentation-at-the-9th-Annual-MASH-TAG-2025-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2491232501","title":"Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2491232501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491232501?lang=en_us&edition=fundamental","pubTime":"2024-12-15 22:16","pubTimestamp":1734272203,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sgmt/sagimet-biosciences/news/sagimet-biosciences-nasdaqsgmt-is-in-a-good-position-to-deli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","QLD","BK4139","LU2210149790.SGD","BK4585","IE00B3QW5Z07.USD","SQQQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","USJW.SI","QID","NDAQ",".IXIC","TSYW.SI","NVIW.SI","USAW.SI","PSQ","SGMT","BK4112","LU2095319765.USD","NQmain","TQQQ","LU2210150020.SGD","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2489781269","title":"Analysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489781269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489781269?lang=en_us&edition=fundamental","pubTime":"2024-12-08 16:40","pubTimestamp":1733647206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chromadex (CDXC – Research Report) and Sagimet Biosc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-chromadex-cdxc-and-sagimet-biosciences-inc-class-a-sgmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","HCSG","CDXC","BK4139","BK4121","BK4137"],"gpt_icon":0},{"id":"2489237474","title":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2489237474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489237474?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:02","pubTimestamp":1733500955,"startTime":"0","endTime":"0","summary":"BUZZ-Sagimet rises as Oppenheimer initiates coverage with 'outperform'** Drug developer Sagimet Biosciences' SGMT.O shares rise 8.4% to $5.05** Oppenheimer starts coverage with \"outperform\" rating and PT at $30 — a 543.8% premium to Thursday's close of $4.66** Brokerage sees \"underappreciated opportunity\" in co's lead experimental drug, denifanstat, being developed to treat metabolic dysfunction-associated steatohepatitis ** MASH is a severe liver disease caused by fat buildup, leading to inflammation and damage** The MASH market is dominated by Madrigal Pharmaceuticals' MDGL.O Rezdiffra** \"We see SGMT as ultimately benefiting from MDGL's build-out of the MASH market as diagnosis rates and reimbursement improve,\" brokerage says ** Oppenheimer expects risk-adjusted peak total revenues of ~$1.9 bln for denifanstat in 2040      ** Including session's move, stock down 8.5% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3N3N70WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","MDGL"],"gpt_icon":0},{"id":"2489252350","title":"Oppenheimer Initiates Sagimet Biosciences at Outperform With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2489252350","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489252350?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:51","pubTimestamp":1733493115,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2489814052","title":"Sagimet Biosciences Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489814052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489814052?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:27","pubTimestamp":1733488020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 07:27 ET (12:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","OPY"],"gpt_icon":0},{"id":"2489247601","title":"Sagimet Biosciences Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2489247601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489247601?lang=en_us&edition=fundamental","pubTime":"2024-12-06 14:28","pubTimestamp":1733466501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N7028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2489153644","title":"Sagimet Biosciences initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2489153644","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489153644?lang=en_us&edition=fundamental","pubTime":"2024-12-06 05:17","pubTimestamp":1733433443,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $30 price target Published first on TheFly – the ultimat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-initiated-with-an-outperform-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","SGMT"],"gpt_icon":0},{"id":"2486183077","title":"Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486183077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486183077?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:00","pubTimestamp":1732626000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov.  26, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/26/2987446/0/en/Sagimet-Biosciences-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","SGMT","BK4139","BK4137"],"gpt_icon":0},{"id":"2484903475","title":"Sagimet Biosciences participates ik,on No","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903475?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:00","pubTimestamp":1732050020,"startTime":"0","endTime":"0","summary":"Biotech Analyst Agrawal holds a conference call with CEO Happel and CFO Chauche on November 22 at 12 pm hosted by Cantor Fitzgerald. ():(https://ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-participates-ikon-no?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.07},{"period":"1month","weight":0.0192},{"period":"3month","weight":-0.1015},{"period":"6month","weight":0.5455},{"period":"1year","weight":-0.5092},{"period":"ytd","weight":-0.0556}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction